|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Since the molecular testing of colon tumors for MLH1 expression is a clinical standard we believe that MLH1 is a much better marker and a greater number of patients would benefit from KU60648 treatment.
|
28224663 |
2017 |
|
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1.
|
25043185 |
2014 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
Colonic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
We studied a set of 46 MSI-H colon tumors cases with MLH1 promoter methylation which was enriched for patients with an age of onset below 50 years (n=13).
|
20444249 |
2010 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer.
|
18615680 |
2008 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Linoleic acid, the most abundant polyunsaturated fatty acid in the diet, was associated with increased risk of colon tumors with only a KRAS mutation and no additional truncating APC mutation or lack of MLH1 expression (RR = 1.41, 95% CI 1.18-1.69 for one standard deviation (i.e., 7.5 g/day) increase in intake, p-trend over the quartiles of intake <0.001).
|
17636402 |
2007 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells.
|
17914563 |
2007 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In contrast, it was positively associated with APC(+) colon tumors in men (highest vs. lowest tertile: RR 2.77, 95% CI 1.29-5.95, P(trend) = 0.008) and was even stronger when the lack of hMLH1 expression and K-ras mutations were excluded (RR 3.99, 95% CI 1.43-11.14, P(trend) = 0.007).
|
17116713 |
2006 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
|
16106253 |
2005 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression of the hMLH1 and hMSH2 proteins in normal tissues: relationship to cancer predisposition in hereditary non-polyposis colon cancer.
|
15735976 |
2005 |
|
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we report a striking association of BRAF, but not of APC, KRAS2, AXIN2, and TP53 mutations, with proximal mismatch-repair-deficient colon tumors and MLH1 hypermethylation.
|
14695993 |
2004 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Ten percent of tumors showed loss of hMLH1 expression and 1.2% showed loss of hMSH2 expression. hMLH1 loss was more frequent in women (P < .001), older patients (P = .004), earlier stage tumors (P = .0001), and proximal colon tumors ( P < .0001).
|
15551255 |
2004 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Colorectal cancer prevention.
|
15375803 |
2004 |
|
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
As candidates for PMS2 mutations, we selected seven patients whose colon tumors stained negative for PMS2 and positive for MLH1 by immunohistochemistry.
|
15256438 |
2004 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetics supersedes epigenetics in colon cancer phenotype.
|
12957287 |
2003 |
|
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These four colorectal tumors, a colon tumor cell line (SW48) and an endometrial tumor cell line (AN3CA), did not express hMLH1, despite the absence of mutations in its coding sequence.
|
9041175 |
1997 |
|
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The repair deficiency was complemented by a colon tumor cell extract that was defective in the hMLH1 protein but not by an extract defective in hMSH2 protein.
|
7585651 |
1995 |
|
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The human colon tumor cell line HCT116 is deficient in wild-type hMLH1, is defective in mismatch repair (MMR), exhibits microsatellite instability, and is tolerant to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
|
7641183 |
1995 |
|
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The human colon tumor cell line HCT 116 is known to have a homozygous mutation in the mismatch repair gene hMLH1 on human chromosome 3, to exhibit microsatellite instability, and to be defective in mismatch repair.
|
8044777 |
1994 |